Defunct Company
Total Trials
10
As Lead Sponsor
As Collaborator
0
Total Enrollment
843
NCT00829582
Intravenous Dose-Escalation Study With ETI-204 in Adult Volunteers
Phase: Phase 1
Role: Lead Sponsor
Start: Feb 28, 2009
Completion: Sep 30, 2009
NCT01453907
Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers
Start: Oct 31, 2011
Completion: Dec 31, 2012
NCT01929226
Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers
Start: Jul 9, 2013
Completion: Nov 29, 2013
NCT01932242
Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers
Start: Jul 23, 2013
Completion: Apr 19, 2014
NCT01932437
Intramuscular Dose-Escalation Study With ETI-204 in Adult Volunteers
Start: Jul 26, 2013
Completion: Jul 3, 2014
NCT01952444
Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers
Start: Oct 29, 2013
Completion: Apr 9, 2014
NCT04421105
A Double-blind, Placebo-controlled Study to Evaluate Very Low Dose LSD in Healthy Volunteers Aged 55-75 Years
Start: Jun 29, 2015
Completion: Nov 5, 2015
NCT05674669
A Dose-Ranging Study of 50 µg to 100 µg LSD in Healthy Volunteers
Start: Oct 20, 2015
Completion: Jul 17, 2017
NCT05434156
ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression
Phase: Phase 1/2
Start: Oct 27, 2022
Completion: Mar 31, 2026
NCT03088111
An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis
Phase: Phase 4
Start: Dec 31, 2023
Completion: Dec 31, 2025